Last €14.28 EUR
Change Today -0.15 / -1.04%
Volume 11.6K
IBAB On Other Exchanges
EN Brussels
As of 6:12 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

ion beam applications (IBAB) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/6/14 - €14.79
52 Week Low
10/25/13 - €6.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ION BEAM APPLICATIONS (IBAB)

Related News

No related news articles were found.

ion beam applications (IBAB) Related Businessweek News

No Related Businessweek News Found

ion beam applications (IBAB) Details

Ion Beam Applications SA operates as a cancer diagnostics and treatment equipment company in Belgium, the United States, and internationally. The company develops, manufactures, and supports medical devices and software solutions for cancer treatment by proton beam therapy. It operates in two segments, Proton therapy and Particle accelerators, and Dosimetry. The Proton therapy and Particle accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of Positron Emission Tomography or Single Photon Emission Computed Tomography radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment offers measurement and quality assurance instruments for radiotherapy and medical imaging to enable the healthcare professionals to verify that equipment administers the planned dose to the targeted area. The company was founded in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

1,037 Employees
Last Reported Date: 04/12/14
Founded in 1986

ion beam applications (IBAB) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: €615.0K
Compensation as of Fiscal Year 2013.

ion beam applications (IBAB) Key Developments

Ion Beam Applications S.A. and Royal Philips Collaborate on Diagnosis and Treatment of Cancer

Ion Beam Applications S.A., or IBA and Royal Philips have signed a global collaboration agreement to provide diagnostic and therapeutic solutions for the treatment of cancer. The collaboration covers sales, marketing, R&D of imaging and therapy solutions in oncology. By merging their respective expertise in therapy and image guidance systems, IBA and Philips will innovate with an integrated vision for more efficient, personalized cancer care. Leveraging high quality imaging and proton therapy offers the potential to increase confidence in the diagnosis and treatment of cancer, reduce short- and long-term side-effects and potentially enhance the quality of life of the patient before, during and after treatment, while reducing the cost of treatment for the healthcare system. The collaboration will also enable both organizations to mutually leverage technologies and solutions: IBA will benefit from Philips diagnostic imaging products offered to oncology care centers, while Philips will leverage IBA proton therapy solutions within its offering for customers in select markets around the world. The commercial collaboration also includes an integrated offering for Molecular Imaging Centers, combining IBA's expertise in PET radioisotope production centers with Philips imaging and diagnostics expertise.

Ion Beam Applications, S.A. Reports Consolidated Earnings Results for the First Half of 2014; Provides Earnings Guidance for the Full Year 2014

Ion Beam Applications, S.A. reported consolidated earnings results for the first half of 2014. For the period, the company reported sales & services of EUR 98.159 million against EUR 97.379 million a year ago. Recurring earnings before interest, taxes, depreciation and amortization was EUR 12.251 million against EUR 10.297 million a year ago. Recurring earnings before interest and taxes was EUR 9.645 million against EUR 8.291 million a year ago. Net profit was EUR 7.441 million against EUR 4.129 million a year ago. The company reported that it is on track to achieve guidance of 5-10% revenue growth for the full year and to reach 10% REBIT margin target in 2014.

Ion Beam Applications, S.A., H1 2014 Earnings Call, Aug 28, 2014

Ion Beam Applications, S.A., H1 2014 Earnings Call, Aug 28, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBAB:BB €14.28 EUR -0.15

IBAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $37.86 USD +0.32
Analogic Corp $71.20 USD +1.20
Balchem Corp $60.48 USD +1.14
Quidel Corp $26.20 USD +0.36
Volcano Corp $10.38 USD -0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation IBAB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 4.0x
Price/Cash Flow 163.8x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ION BEAM APPLICATIONS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at